Cystic Fibrosis Patients in Canada Live Longer Than Those in U.S.
Canadians with cystic fibrosis live about 10 years longer on average, researchers say (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 15, 2017 Category: Respiratory Medicine Tags: Family Medicine, Internal Medicine, Nursing, Pathology, Pediatrics, Pulmonology, Journal, Source Type: news

Cystic Fibrosis Survival Better in Canada Than in U.S.
Canadians with the lung disease live about 10 years longer on average, study finds Source: HealthDay Related MedlinePlus Page: Cystic Fibrosis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 14, 2017 Category: Consumer Health News Source Type: news

Cystic Fibrosis Survival Better in Canada Than in U.S.
Title: Cystic Fibrosis Survival Better in Canada Than in U.S.Category: Health NewsCreated: 3/13/2017 12:00:00 AMLast Editorial Review: 3/14/2017 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - March 14, 2017 Category: Respiratory Medicine Source Type: news

Cystic Fibrosis Survival Better in Canada Than in U.S.
Canadians with the lung disease live about 10 years longer on average, study finds (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 14, 2017 Category: Respiratory Medicine Authors: webmaster at doctorslounge.com Tags: Family Medicine, Nursing, Pulmonology, Nutrition, Organ Transplants, News, Source Type: news

Canadians with Cystic Fibrosis Live Roughly 10 Years Longer Than Americans (FREE)
By Kelly Young Edited by Jaye Elizabeth Hefner, MD Canadian patients with cystic fibrosis have a survival advantage over their U.S. counterparts, according to a study in the Annals of Internal Medicine. … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 13, 2017 Category: Primary Care Source Type: news

Cystic fibrosis patients live 10 years longer in Canada
Although the neighboring countries have the same proportion of cystic fibrosis patients, Canadians are far more likely to receive a lung transplant than Americans with the same incurable disease. (Source: the Mail online | Health)
Source: the Mail online | Health - March 13, 2017 Category: Consumer Health News Source Type: news

Canadians With Cystic Fibrosis Outlive US Patients by 10 Years Canadians With Cystic Fibrosis Outlive US Patients by 10 Years
Differences between the health systems in the United States and Canada, including access to transplants, likely explain why Canadian patients with CF live longer than their US counterparts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 13, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Cystic fibrosis patients live longer in Canada than in U.S.
(Reuters Health) - Canadians with cystic fibrosis, a life threatening inherited disorder of the lungs and digestive system, tend to survive about a decade longer than American patients, a new study suggests. (Source: Reuters: Health)
Source: Reuters: Health - March 13, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

CF patients survive 10 years longer in Canada than in US
Canadians with cystic fibrosis live, on average, 10 years longer than their counterparts in the United States, according to a study published Monday in Annals of Internal Medicine. (Source: CNN.com - Health)
Source: CNN.com - Health - March 13, 2017 Category: Consumer Health News Source Type: news

Why Canadians with cystic fibrosis live 10 years longer than patients in U.S.
Over the last two decades there’s been a big improvement in survival rates for people with cystic fibrosis, with patients in Canada living 10 years longer than those in the U.S. (Source: CBC | Health)
Source: CBC | Health - March 13, 2017 Category: Consumer Health News Tags: News/Health Source Type: news

Cystic Fibrosis Survival: 10-Year Advantage in Canada vs U.S. (CME/CE)
(MedPage Today) -- Median survival was 50.9 years in Canada, 40.6 years in U.S. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 13, 2017 Category: Primary Care Source Type: news

Cystic Fibrosis Survival Better in Canada Than in U.S.
MONDAY, March 13, 2017 -- People with cystic fibrosis are living longer than ever, but those in Canada live nearly 10 years longer than those in the United States, a new study finds. Cystic fibrosis is a genetic disease that affects the lungs and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 13, 2017 Category: Journals (General) Source Type: news

Phage therapy shown to kill drug-resistant superbug
Phage therapy could offer a safe and effective alternative to antibiotics in the treatment of Cystic Fibrosis lung infections, researchers have demonstrated. Phages are viruses that kill bacteria but are otherwise harmless. A major advantage is that phages only target the harmful bacteria, so there are less side of the effects often associated with antibiotics. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 13, 2017 Category: Science Source Type: news

Phage therapy shown to kill drug-resistant superbug
Scientists from the University of Liverpool have shown that phage therapy could offer a safe and effective alternative to antibiotics in the treatment of Cystic Fibrosis lung infections. Chronic lung infections caused by the bacterium Pseudomonas aeruginosa are becoming increasingly difficult to treat due to antimicrobial resistance (AMR). With limited alternative therapeutic options available this has led to a renewed interest in (bacterio)phage therapy. (Source: World Pharma News)
Source: World Pharma News - March 13, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Study finds differences in lifespan between Canadians and Americans with cystic fibrosis
(Source: St. Michael's Hospital News and Media)
Source: St. Michael's Hospital News and Media - March 13, 2017 Category: Hospital Management Tags: Hospital News Source Type: news

Phage therapy shown to kill drug-resistant superbug
(University of Liverpool) Scientists from the University of Liverpool have shown that phage therapy could offer a safe and effective alternative to antibiotics in the treatment of cystic fibrosis lung infections. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 13, 2017 Category: Infectious Diseases Source Type: news

Vertex to acquire Concert Pharmaceuticals ’ cystic fibrosis drug for $250m
US-based Vertex Pharmaceuticals has signed an agreement to acquire CTP-656, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator from Concert Pharmaceuticals for up to $250m. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 7, 2017 Category: Pharmaceuticals Source Type: news

Mast Therapeutics subsidiary advances trial for inhaled sodium nitrite solution
Mast Therapeutics (NYSE:MSTX) said today that its subsidiary Aires Pharmaceuticals inked a deal with the University of Pittsburgh related to its phase 1/2 open-label proof-of-concept trial for the company’s AIR001 inhaled sodium nitrite solution in patients with cystic fibrosis. The study will evaluate the nebulized drug as a treatment of Pseudomonas aeruginosa infection in CF patients, according to Mast. The subsidiary plans to provide the drug and nebulizers for the study, but no financial support. Get the full story at our sister site, Drug Delivery Business News. The post Mast Therapeutics subsidiary advance...
Source: Mass Device - March 6, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat Mast Therapeutics Source Type: news

$160M deal with Concert helps Vertex maintain dominance in cystic fibrosis
Vertex Pharmaceuticals' move on Monday to acquire a once-a-day cystic fibrosis drug for $160 million from a 69-employee Lexington-based biotech could help the Boston company maintain its "dominant" position in the CF pharmaceuticals market, according to one analyst. It could also help the smaller biotech, Concert Pharmaceuticals (Nasdaq: CNCE), head off a possible lawsuit in its future. The deal is part of an effort by Boston-based Vertex (Nasdaq: VRTX) to develop combination-drug regimens that… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 6, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

PTC says to abandon cystic fibrosis drug after trial failure
(Reuters) - PTC Therapeutics Inc said on Thursday it would stop developing its cystic fibrosis drug after it failed to meet the main goal of a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - March 2, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Antibiotics used to treat cystic fibrosis increases risk of permanent hearing loss
A powerful class of antibiotics provides life-saving relief for people with cystic fibrosis; however, a new study for the first time reveals the levels at which high cumulative dosages over time significantly increases the risk of permanent hearing loss in these patients. The study suggests physicians who treat patients with cystic fibrosis may be able to consider alternative strategies for treating the symptoms of respiratory infections associated with CF. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 25, 2017 Category: Science Source Type: news

ACOG Recommends Offering All Pregnant Women Additional Carrier Screening (FREE)
By Kelly Young Edited by William E. Chavey, MD, MS All women who are pregnant or are considering becoming pregnant should be offered carrier screening for cystic fibrosis and spinal muscular atrophy and a … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 23, 2017 Category: Primary Care Source Type: news

Paul Ryan Makes The Simplistic Case For Obamacare Repeal: You'll Be Free
House Speaker Paul Ryan (R-Wis.) says that repealing Obamacare is all about freedom. He’s right, although perhaps not in the way he thinks. On Tuesday, Ryan tweeted an argument that he and other conservative leaders have made many times before: “Freedom is the ability to buy what you want to fit what you need. Obamacare is Washington telling you what to buy regardless of your needs.” Freedom is the ability to buy what you want to fit what you need. Obamacare is Washington telling you what to buy regardless of your needs.— Paul Ryan (@PRyan) February 21, 2017 There’s some truth i...
Source: Healthy Living - The Huffington Post - February 22, 2017 Category: Consumer Health News Source Type: news

Student, 18, with cystic fibrosis becomes a cheerleader
Emily Bonney, 18, pictured, from Blackpool, takes up to 60 tablets every day to keep her lungs functioning at a normal rate - but this didn't stop her joining the squad. (Source: the Mail online | Health)
Source: the Mail online | Health - February 15, 2017 Category: Consumer Health News Source Type: news

Overcoming hurdles in CRISPR gene editing to improve treatment
The new gene-editing tool CRISPR/Cas9 holds promise for new treatment of such genetic diseases as cystic fibrosis, muscular dystrophy and hemophilia. But to work well, it must be delivered across the cell membrane and into its nucleus, a process that can trigger cell defenses and'trap'CRISPR/Cas9, reducing its treatment potential. Now, a research team has designed a delivery system using nanoparticles to assist CRISPR/Cas9 across the membrane and avoid entrapment by cellular machinery. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 7, 2017 Category: Science Source Type: news

Overcoming hurdles in CRISPR gene editing to improve treatment
(University of Massachusetts at Amherst) The new gene-editing tool CRISPR/Cas9 holds promise for new treatment of such genetic diseases as cystic fibrosis, muscular dystrophy and hemophilia. But to work well, it must be delivered across the cell membrane and into its nucleus, a process that can trigger cell defenses and 'trap' CRISPR/Cas9, reducing its treatment potential. Now, Vincent Rotello's laboratory at UMass Amherst has designed a delivery system using nanoparticles to assist CRISPR/Cas9 across the membrane and avoid entrapment by cellular machinery. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 7, 2017 Category: Biology Source Type: news

Pulmatrix raises $3m in direct offering
Pulmatrix (NSDQ:PULM) said today that unnamed institutional investors agreed to purchase approximately $3.3 million of shares of common stock in a direct offering. The company said it plans to sell 950,000 shares at $3.50 apiece. Pulmatrix expects the offering, which will close next week, to bring in $3.0 million in proceeds to use for general corporate purposes and paying off some of its debt. The company saw its stock price soar in January after its drug candidate for treating fungal infections in the lungs of cystic fibrosis patients was designated as a ‘qualified infectious disease product’ by the FDA. Foll...
Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news

Updated cystic fibrosis diagnosis guidelines can help in diagnosis, personalized treatment
An international research group of 32 experts from nine countries has updated the guidelines for diagnosing the genetic disease cystic fibrosis. The researchers expect that these guidelines will provide better direction for clinicians looking at patients with symptoms of the disease to make a correct diagnosis and recommend personalized treatment. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 31, 2017 Category: Science Source Type: news

Updated cystic fibrosis diagnosis guidelines can help in diagnosis, personalized treatment
(Johns Hopkins Medicine) An international research group of 32 experts from nine countries has updated the guidelines for diagnosing the genetic disease cystic fibrosis. The researchers expect that these guidelines will provide better direction for clinicians looking at patients with symptoms of the disease to make a correct diagnosis and recommend personalized treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 31, 2017 Category: Global & Universal Source Type: news

Fighting age-related fibrosis to keep organs young
Their research indicates that an already-FDA-approved drug used by cystic fibrosis patients could shield our organs from fibrosis during acute events, like lung infection or heart attack. And looking to the future, they envision that the development of a once-daily pill, capable of inhibiting PAD4, could one day be used as a preventative measure. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 30, 2017 Category: Science Source Type: news

Fighting age-related fibrosis to keep organs young
(Boston Children's Hospital) Their research indicates that an already-FDA-approved drug used by cystic fibrosis patients could shield our organs from fibrosis during acute events, like lung infection or heart attack. And looking to the future, they envision that the development of a once-daily pill, capable of inhibiting PAD4, could one day be used as a preventative measure. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 30, 2017 Category: Global & Universal Source Type: news

‘ They brought me back from death ’: How a woman survived six days without lungs
Melissa Benoit's lungs had been weakened by cystic fibrosis and ravaged by bacterial infections for three years. Then, last February, a bout of swine flu sent her spiraling toward death. By April, she gasped for air with every breath. She had coughing fits so intense her ribs fractured. Her lungs were as hard as a […]Related:Mold-contaminated mouth rinse found at NIH, spokeswoman saysDrug company to help improve Virginia’s prescription drug monitoring systemShe was a model. Then a mysterious digestive disorder starved her to death. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - January 27, 2017 Category: Consumer Health News Source Type: news

Doctors save woman's life by removing her lungs for 6 days
Melissa Benoit, was born with cystic fibrosis, but doctors at Toronto General Hospital discovered she had just hours to live when she was rushed there with a severe infection in April. (Source: the Mail online | Health)
Source: the Mail online | Health - January 26, 2017 Category: Consumer Health News Source Type: news

What is in the Differential Diagnosis of Fatigue?
Discussion Fatigue is a subjective feeling of decreased energy, tiredness or feeling of exhaustion. Lethargy is often used synonymously, but lethargy is a state of being drowsiness or sleepy, and implies mental status changes. Both can cause the person to be apathetic or less active. Fatigue is a common state that almost everyone experiences multiple times in his or her lifetime. For most people it is a relatively acute or short-term chronic problem, often with a relatively easily identifiable problem cause, such as inadequate sleep, acute illness, or overexertion. For some, it can be less readily identifiable such as dep...
Source: PediatricEducation.org - January 23, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Pulmatrix shares soar after winning FDA designation
Pulmatrix (NSDQ:PULM) shares were up 159% to $1.79 apiece in mid-afternoon trading today after the company announced that its drug candidate for treating fungal infections in the lungs of cystric fibrosis patients was designated as a ‘qualified infectious disease product’ by the FDA. With the designation, the Lexington, Mass.-based company will receive 5 years of market exclusivity for the drug candidate. “The new QIDP designation is a significant boost to our efforts to make this drug available as quickly as possible to cystic fibrosis patients suffering from fungal lung infections,” Pulmatrix CEO ...
Source: Mass Device - January 17, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Clearance Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news

High-risk patient gets life-saving transplant when UCLA team accepts her case
A 24-year-old cystic fibrosis patient is starting the new year with new hope thanks to help from the U.S. Air Force, the actor who played Chewbacca in the “Star Wars” movies and a UCLA surgeon who said yes to a high-risk case.Kathlyn Chassey of San Antonio, Texas, was born with cystic fibrosis, a genetic disease characterized by the build-up in the lungs of thick, sticky mucus that traps infection-causing bacteria. While there is no cure, lung transplantation can help alleviate many of the symptoms.Courtesy of the Chassey familyKathlyn Chassey walks after her lung transplant surgery at Reagan UCLA Medical Cente...
Source: UCLA Newsroom: Health Sciences - January 14, 2017 Category: Universities & Medical Training Source Type: news

Cystic Fibrosis: Caroline Is In Control
LMU student Caroline Schambeck has Cystic fibrosis, a genetic disease, but she does not let her illness dominate her life (Source: Disabled World)
Source: Disabled World - January 13, 2017 Category: Disability Tags: Cystic Fibrosis Source Type: news

Mast Therapeutics, Savara ink merger deal
Mast Therapeutics (NYSE:MSTX) and privately-held Savara Inc. said today that the 2 companies have landed a definitive merger agreement, combining their operations. The newly-formed Austin, Texas-based company is expected to be named Savara Inc., and trade on the NYSE market under a new ticker symbol. The combined company will focus on advancing a pipeline of inhaled therapies, including AeroVanc to treat chronic methicillin-resistant Staphylococcus aureus pulmonary infection in cystic fibrosis, Molgradex to treat pulmonary alveolar proteinosis and AIR1001 to treat heart failure with preserved ejection fraction. All 3 ...
Source: Mass Device - January 9, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Mergers & Acquisitions Pharmaceuticals Respiratory Wall Street Beat Mast Therapeutics Savara Inc. Source Type: news

​Vertex sales prediction for top-selling drug lower than hoped
In a highly anticipated announcement today in San Francisco, executives from Vertex Pharmaceuticals told investors they expect $1.1 billion to $1.3 billion in sales of the cystic fibrosis drug Orkambi this year, falling short of most expectations. Boston-based Vertex (Nasdaq: VRTX) made the announcement at the J.P. Morgan Healthcare Conference Sunday afternoon, one of the first of what will likely be several big announcements from local biotech companies over the next several days. The 2017 guidance… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 9, 2017 Category: Biotechnology Authors: Don Seiffert Source Type: news

​Vertex sales prediction for top-selling drug lower than hoped
In a highly anticipated announcement today in San Francisco, executives from Vertex Pharmaceuticals told investors they expect $1.1 billion to $1.3 billion in sales of the cystic fibrosis drug Orkambi this year, falling short of most expectations. Boston-based Vertex (Nasdaq: VRTX) made the announcement at the J.P. Morgan Healthcare Conference Sunday afternoon, one of the first of what will likely be several big announcements from local biotech companies over the next several days. The 2017 guidance… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 8, 2017 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

Lumacaftor-Ivacaftor Combination Effective for Some Cystic Fibrosis Patients Lumacaftor-Ivacaftor Combination Effective for Some Cystic Fibrosis Patients
The combination of lumacaftor and ivacaftor is effective for the long-term treatment of patients with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation, according to the PROGRESS study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 4, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Colorado biotech to streamline operations, explore alternatives after clinical trial failure
A Boulder maker of experimental cystic fibrosis drugs is cutting back and has begun exploring “strategic alternatives” a month after its lead compound disappointed in clinical trials. Nivalis Therapeutics (Nasdaq: NVLS) hired advisory firm Ladenburg Thalmann& Co. Inc. to help the Nivalis board consider alternatives, including a possible sale, acquisition or merger for the business, the company said. Nivalis also intends to streamline its operations as it focuses on “maximizing stockholder… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 4, 2017 Category: Biotechnology Authors: Greg Avery Source Type: news

Colorado biotech to streamline operations, explore alternatives after clinical trial failure
A Boulder maker of experimental cystic fibrosis drugs is cutting back and has begun exploring “strategic alternatives” a month after its lead compound disappointed in clinical trials. Nivalis Therapeutics (Nasdaq: NVLS) hired advisory firm Ladenburg Thalmann& Co. Inc. to help the Nivalis board consider alternatives, including a possible sale, acquisition or merger for the business, the company said. Nivalis also intends to streamline its operations as it focuses on “maximizing stockholder… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 4, 2017 Category: Pharmaceuticals Authors: Greg Avery Source Type: news

A Surprising Lower Airway Infection A Surprising Lower Airway Infection
What lessons can be learned from the surprising cause of a lower airway infection in a child with cystic fibrosis?Thorax (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - January 2, 2017 Category: Radiology Tags: Pulmonary Medicine Journal Article Source Type: news

Anthera's cystic fibrosis drug fails late-stage study, shares tank
(Reuters) - Anthera Pharmaceuticals Inc said on Tuesday that its drug to treat certain cystic fibrosis patients failed a late-stage study, sending the company's shares tumbling nearly 70 percent in after-hours trading. (Source: Reuters: Health)
Source: Reuters: Health - December 27, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Death and Taxes – The Certainty of Life
Yet in the medical and pharmaceutical world, this continual pounding was offset by my personal encounters with some outstanding people – whose deaths, or the work they did with the dying, taught me about how much more we can do to facilitate a better end of life for patients. After all, even when drugs cease to be useful, physical and emotional needs still persist.It ’s about the little thingsAn English geriatrician and campaigner for better patient care,Kate Granger, founded the‘Hello my name is…’ campaign in the UK. Designed to encourage doctors to introduce themselves to patients as a prio...
Source: EyeForPharma - December 22, 2016 Category: Pharmaceuticals Authors: Emma D ' arcy Source Type: news

Bacterial'Sabotage' Drives Cystic Fibrosis Inflammation (CME/CE)
(MedPage Today) -- Inhibiting Cif enzyme could be novel treatment for CF (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - December 18, 2016 Category: Infectious Diseases Source Type: news

Cochrane Priority Reviews List: Update
February 2017 UpdateThe February 2017 revision of the Cochrane Priority Reviews List includes new titles from the Cochrane Acute Respiratory Infections, Cystic Fibrosis& Genetic Disorders, ENT, Musculoskeletal, and Wounds Groups.The following titles on the list are open to new authors:Biomarkers for predicting outcomes in endometrial cancer (Gynaecological, Neuro-oncology and Orphan Cancer)Diagnostic test accuracy of sentinel LN node sampling in endometrial cancer (Gynaecological, Neuro-oncology and Orphan Cancer)Immunomodulatory treatment for amyotrophic lateral sclerosis /motor neuron disease (ALS/MND) (Neuromuscular...
Source: Cochrane News and Events - December 14, 2016 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

Bacterial'sabotage' handicaps ability to resolve devastating lung inflammation in cystic fibrosis
The chronic lung inflammation that is a hallmark of cystic fibrosis, has, for the first time, been linked to a new class of bacterial enzymes that hijack the patient ’s immune response and prevent the body from calling off runaway inflammation, according to a laboratory investigation. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 13, 2016 Category: Science Source Type: news